Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin

Virology

Volumn 428, Issue 2, 2012, Pages 98-111

  Dafa Berger, Avis ^a   Kuzmina, Alona ^a   Fassler, Michael ^a   Yitzhak Asraf, Hila ^a   Shemer Avni, Yonat ^a   Taube, Ran ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

BST 2 Tetherin; Hepatitis C virus; HIV vpu; IFN type I innate response; Viral release

Indexed keywords

ALPHA INTERFERON; INTERFERON; PROTEIN TETHERIN; UNCLASSIFIED DRUG;

ARTICLE; BST 2 GENE; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE OVEREXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS PARTICLE; VIRUS RELEASE; VIRUS REPLICATION;

ANTIGENS, CD; GPI-LINKED PROTEINS; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; VIRUS RELEASE;

HEPATITIS C VIRUS;

EID: 84860838280     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.03.011     Document Type: Article

References (84)

1. Aizaki H., Lee K.J., Sung V.M., Ishiko H., Lai M.M. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 2004, 324(2):450-461.
2. Amemiya F., Maekawa S., Itakura Y., Kanayama A., Matsui A., Takano S., Yamaguchi T., Itakura J., Kitamura T., Inoue T., Sakamoto M., Yamauchi K., Okada S., Yamashita A., Sakamoto N., Itoh M., Enomoto N. Targeting lipid metabolism in the treatment of hepatitis C virus infection. J. Infect. Dis. 2008, 197(3):361-370.
3. Andrew A.J., Miyagi E., Strebel K. Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J. Virol. 2011, 85(6):2611-2619.
4. Appel N., Schaller T., Penin F., Bartenschlager R. From structure to function: new insights into hepatitis C virus RNA replication. J. Biol. Chem. 2006, 281(15):9833-9836.
5. Bartenschlager R., Frese M., Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv. Virus Res. 2004, 63:71-180.
6. Bartenschlager R., Penin F., Lohmann V., Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011, 19(2):95-103.
7. Bartosch B., Dubuisson J., Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197(5):633-642.
8. Bartosch B., Vitelli A., Granier C., Goujon C., Dubuisson J., Pascale S., Scarselli E., Cortese R., Nicosia A., Cosset F.L. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 2003, 278(43):41624-41630.
9. Berger K.L., Cooper J.D., Heaton N.S., Yoon R., Oakland T.E., Jordan T.X., Mateu G., Grakoui A., Randall G. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. USA 2009, 106(18):7577-7582.
10. Bigger C.B., Guerra B., Brasky K.M., Hubbard G., Beard M.R., Luxon B.A., Lemon S.M., Lanford R.E. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J. Virol. 2004, 78(24):13779-13792.
11. Blanchard E., Belouzard S., Goueslain L., Wakita T., Dubuisson J., Wychowski C., Rouille Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 2006, 80(14):6964-6972.
12. Chang K.S., Jiang J., Cai Z., Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 2007, 81(24):13783-13793.
13. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244(4902):359-362.
14. Codran A., Royer C., Jaeck D., Bastien-Valle M., Baumert T.F., Kieny M.P., Pereira C.A., Martin J.P. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J. Gen. Virol. 2006, 87(Pt 9):2583-2593.
15. Coller K.E., Berger K.L., Heaton N.S., Cooper J.D., Yoon R., Randall G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog. 2009, 5(12):e1000702.
16. Coller K.E., Heaton N.S., Berger K.L., Cooper J.D., Saunders J.L., Randall G. Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog. 2012, 8(1):e1002466.
17. Counihan N.A., Rawlinson S.M., Lindenbach B.D. Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS Pathog. 2011, 7(10):e1002302.
18. Dietrich I., McMonagle E.L., Petit S.J., Vijayakrishnan S., Logan N., Chan C.N., Towers G.J., Hosie M.J., Willett B.J. Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J. Virol. 2011, 85(12):5840-5852.
19. Douglas J.L., Gustin J.K., Viswanathan K., Mansouri M., Moses A.V., Fruh K. The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog. 2010, 6(5):e1000913.
20. Dube M., Roy B.B., Guiot-Guillain P., Mercier J., Binette J., Leung G., Cohen E.A. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J. Virol. 2009, 83(9):4574-4590.
21. Egger D., Wolk B., Gosert R., Bianchi L., Blum H.E., Moradpour D., Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 2002, 76(12):5974-5984.
22. Erikson E., Adam T., Schmidt S., Lehmann-Koch J., Over B., Goffinet C., Harter C., Bekeredjian-Ding I., Sertel S., Lasitschka F., Keppler O.T. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc. Natl. Acad. Sci. USA 2011.
23. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., Hatziioannou T., McKeating J.A., Bieniasz P.D., Rice C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446(7137):801-805.
24. Foy E., Li K., Sumpter R., Loo Y.M., Johnson C.L., Wang C., Fish P.M., Yoneyama M., Fujita T., Lemon S.M., Gale M. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl. Acad. Sci. USA 2005, 102(8):2986-2991.
25. Gale M., Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436(7053):939-945.
26. Gao L., Aizaki H., He J.W., Lai M.M. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J. Virol. 2004, 78(7):3480-3488.
27. Goffinet C., Allespach I., Homann S., Tervo H.M., Habermann A., Rupp D., Oberbremer L., Kern C., Tibroni N., Welsch S., Krijnse-Locker J., Banting G., Krausslich H.G., Fackler O.T., Keppler O.T. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe. 2009, 5(3):285-297.
28. Goffinet C., Schmidt S., Kern C., Oberbremer L., Keppler O.T. Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. J. Virol. 2010, 84(21):11374-11384.
29. Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H.E., Bienz K., Moradpour D. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J. Virol. 2003, 77(9):5487-5492.
30. Groom H.C., Yap M.W., Galao R.P., Neil S.J., Bishop K.N. Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc. Natl. Acad. Sci. USA 2010, 107(11):5166-5171.
31. Gupta R.K., Mlcochova P., Pelchen-Matthews A., Petit S.J., Mattiuzzo G., Pillay D., Takeuchi Y., Marsh M., Towers G.J. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. USA 2009, 106(49):20889-20894.
32. Haller O., Kochs G., Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 2006, 344(1):119-130.
33. Hauser H., Lopez L.A., Yang S.J., Oldenburg J.E., Exline C.M., Guatelli J.C., Cannon P.M. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 2010, 7:51.
34. He Y., Duan W., Tan S.L. Emerging host cell targets for hepatitis C therapy. Drug Discov. Today 2007, 12(5-6):209-217.
35. Horner S.M., Gale M. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J. Interferon Cytokine Res. 2009, 29(9):489-498.
36. Jiang J., Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J. Virol. 2009, 83(24):12680-12691.
37. Jones D.M., McLauchlan J. Hepatitis C virus: assembly and release of virus particles. J. Biol. Chem. 2010, 285(30):22733-22739.
38. Jouvenet N., Neil S.J., Zhadina M., Zang T., Kratovac Z., Lee Y., McNatt M., Hatziioannou T., Bieniasz P.D. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 2009, 83(4):1837-1844.
39. Kolykhalov A.A., Agapov E.V., Blight K.J., Mihalik K., Feinstone S.M., Rice C.M. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997, 277(5325):570-574.
40. Kupzig S., Korolchuk V., Rollason R., Sugden A., Wilde A., Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003, 4(10):694-709.
41. Le Tortorec A., Neil S.J. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 2009, 83(22):11966-11978.
42. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309(5734):623-626.
43. Lindenbach B.D., Rice C.M. Molecular biology of flaviviruses. Adv. Virus Res. 2003, 59:23-61.
44. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436(7053):933-938.
45. Lopez, L.A., Yang, S.J., Exline, C.M., Rengarajan, S., Haworth, K.G., Cannon, P.M., 2012. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve tetherin removal from lipid rafts. J. Virol.
46. Lopez L.A., Yang S.J., Hauser H., Exline C.M., Haworth K.G., Oldenburg J., Cannon P.M. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J. Virol. 2010, 84(14):7243-7255.
47. Mackenzie J.M., Westaway E.G. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J. Virol. 2011, 75(22):10787-10799.
48. Martin-Serrano J., Neil S.J. Host factors involved in retroviral budding and release. Nat. Rev. Microbiol. 2011, 9(7):519-531.
49. Masuyama N., Kuronita T., Tanaka R., Muto T., Hirota Y., Takigawa A., Fujita H., Aso Y., Amano J., Tanaka Y. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J. Biol. Chem. 2009, 284(23):15927-15941.
50. Merz A., Long G., Hiet M.S., Brugger B., Chlanda P., Andre P., Wieland F., Krijnse-Locker J., Bartenschlager R. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J. Biol. Chem. 2011, 286(4):3018-3032.
51. Miyagi E., Andrew A.J., Kao S., Strebel K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. USA 2009, 106(8):2868-2873.
52. Miyanari Y., Atsuzawa K., Usuda N., Watashi K., Hishiki T., Zayas M., Bartenschlager R., Wakita T., Hijikata M., Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 2007, 9(9):1089-1097.
53. Moradpour D., Gosert R., Egger D., Penin F., Blum H.E., Bienz K. Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral. Res. 2003, 60(2):103-109.
54. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5(6):453-463.
55. Murray C.L., Jones C.T., Rice C.M. Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat. Rev. Microbiol. 2008, 6(9):699-708.
56. Murray, C.L., Rice, C.M., 2011. Turning hepatitis C virus into a real virus. Annu. Rev. Microbiol..
57. Neil S.J., Sandrin V., Sundquist W.I., Bieniasz P.D. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe. 2007, 2(3):193-203.
58. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451(7177):425-430.
59. Ng T.I., Mo H., Pilot-Matias T., He Y., Koev G., Krishnan P., Mondal R., Pithawalla R., He W., Dekhtyar T., Packer J., Schurdak M., Molla A. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology 2007, 45(6):1413-1421.
60. Pardieu C., Vigan R., Wilson S.J., Calvi A., Zang T., Bieniasz P., Kellam P., Towers G.J., Neil S.J. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog. 2010, 6(4):e1000843.
61. Perez-Caballero D., Zang T., Ebrahimi A., McNatt M.W., Gregory D.A., Johnson M.C., Bieniasz P.D. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139(3):499-511.
62. Pezacki J.P., Sagan S.M., Tonary A.M., Rouleau Y., Belanger S., Supekova L., Su A.I. Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus. BMC Chem. Biol. 2009, 9:2.
63. Ploss A., Rice C.M. Towards a small animal model for hepatitis C. EMBO Rep. 2009, 10(11):1220-1227.
64. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., Younossi Z., Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38(1):75-85.
65. Radoshitzky S.R., Dong L., Chi X., Clester J.C., Retterer C., Spurgers K., Kuhn J.H., Sandwick S., Ruthel G., Kota K., Boltz D., Warren T., Kranzusch P.J., Whelan S.P., Bavari S. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J. Virol. 2010, 84(20):10569-10580.
66. Randall G., Panis M., Cooper J.D., Tellinghuisen T.L., Sukhodolets K.E., Pfeffer S., Landthaler M., Landgraf P., Kan S., Lindenbach B.D., Chien M., Weir D.B., Russo J.J., Ju J., Brownstein M.J., Sheridan R., Sander C., Zavolan M., Tuschl T., Rice C.M. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl. Acad. Sci. USA 2007, 104(31):12884-12889.
67. Ruiz A., Lau D., Mitchell R.S., Hill M.S., Schmitt K., Guatelli J.C., Stephens E.B. BST-2 mediated restriction of simian-human immunodeficiency virus. Virology 2010, 406(2):312-321.
68. Saito T., Gale M. RIG-I mediated hepatic innate immune signaling that controls HCV infection. Uirusu 2008, 58(2):105-115.
69. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H., Christen V., Terracciano L., Filipowicz W., Heim M.H. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA 2008, 105(19):7034-7039.
70. Sauter D., Schindler M., Specht A., Landford W.N., Munch J., Kim K.A., Votteler J., Schubert U., Bibollet-Ruche F., Keele B.F., Takehisa J., Ogando Y., Ochsenbauer C., Kappes J.C., Ayouba A., Peeters M., Learn G.H., Shaw G., Sharp P.M., Bieniasz P., Hahn B.H., Hatziioannou T., Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6(5):409-421.
71. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472(7344):481-485.
72. Sen G.C., Sarkar S.N. The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses. Curr. Top Microbiol. Immunol. 2007, 316:233-250.
73. Sklan E.H., Charuworn P., Pang P.S., Glenn J.S. Mechanisms of HCV survival in the host. Nat. Rev. Gastroenterol. Hepatol. 2009, 6(4):217-227.
74. Su A.I., Pezacki J.P., Wodicka L., Brideau A.D., Supekova L., Thimme R., Wieland S., Bukh J., Purcell R.H., Schultz P.G., Chisari F.V. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2002, 99(24):15669-15674.
75. Sumpter R., Loo Y.M., Foy E., Li K., Yoneyama M., Fujita T., Lemon S.M., Gale M. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 2005, 79(5):2689-2699.
76. Taguchi T., Nagano-Fujii M., Akutsu M., Kadoya H., Ohgimoto S., Ishido S., Hotta H. Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J. Gen. Virol. 2004, 85(Pt 4):959-969.
77. Tai A.W., Benita Y., Peng L.F., Kim S.S., Sakamoto N., Xavier R.J., Chung R.T. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009, 5(3):298-307.
78. Tscherne D.M., Jones C.T., Evans M.J., Lindenbach B.D., McKeating J.A., Rice C.M. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 2006, 80(4):1734-1741.
79. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3(4):245-252.
80. Van Damme N., Guatelli J. HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes. Cell Microbiol. 2008, 10(5):1040-1057.
81. Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 2000, 20(1):1-16.
82. Watanabe R., Leser G.P., Lamb R.A. Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology 2011, 417(1):50-56.
83. Williams R. Global challenges in liver disease. Hepatology 2006, 44(3):521-526.
84. Ye, L., Wang, X., Li, J., Liu, J., Ramirez, S.H., Wu, J., Ho, W., Tetherin has negligible activity in restricting hepatitis C virus in hepatocytes. Innate Immun. in press.